Literature DB >> 17724172

AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter.

Shahrokh C Khani1, Basil S Pawlyk, Oleg V Bulgakov, Eileen Kasperek, Joyce E Young, Michael Adamian, Xun Sun, Alexander J Smith, Robin R Ali, Tiansen Li.   

Abstract

PURPOSE: Gene therapy for retinal degeneration requires well-defined promoters that drive expression in rod and cone photoreceptors. This study was undertaken to develop short, active derivatives of the human rhodopsin kinase (RK) gene promoter for targeting transgene expression in rods and cones. RK, also known as G protein-coupled receptor kinase 1 (GRK1), is a component of the light adaptation pathway expressed in rods and cones.
METHODS: Human RK (hRK) promoter and its concatemers or derivatives extending into the conserved 5' untranslated region (5'-UTR) were assayed for promoter activity in WERI retinoblastoma or Crx/Sp1-supplemented HEK-293 cells. The derivative displaying the highest activity was linked to a GFP reporter and packaged in a pseudotyped adenoassociated viral vector (AAV2/5). The AAV vector was tested in vivo by subretinal injections in wild-type mice, in the all-cone Nrl(-/-) mice, and in the cone-rich diurnal Nile grass rat (Arvicanthis niloticus). Control eyes received a similar AAV2/5 vector carrying a mouse rod opsin (mOps) promoter-controlled GFP reporter.
RESULTS: The hRK promoter with the full 5' untranslated sequence (-112 to +180) was the most active in cell culture. Delivered by the AAV2/5 vector, RK promoter drove GFP expression specifically in photoreceptors. In rods, hRK promoter-mediated expression was as efficient as, but appeared more uniform than, mOps promoter-mediated expression. In cones, the hRK promoter drove expression, whereas the mOps promoter did not.
CONCLUSIONS: The hRK promoter is active and specific for rod and cone photoreceptors. Because of its small size and proven activity in cones, it is a promoter of choice for somatic gene transfer and gene therapy targeting rods and cones.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724172     DOI: 10.1167/iovs.07-0257

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  62 in total

1.  A 350 bp region of the proximal promoter of Rds drives cell-type specific gene expression.

Authors:  Xue Cai; Shannon M Conley; Tong Cheng; Muayyad R Al-Ubaidi; Muna I Naash
Journal:  Exp Eye Res       Date:  2010-05-04       Impact factor: 3.467

2.  A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration.

Authors:  Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

3.  Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors.

Authors:  Sanford L Boye; Antonette Bennett; Miranda L Scalabrino; K Tyler McCullough; Kim Van Vliet; Shreyasi Choudhury; Qing Ruan; James Peterson; Mavis Agbandje-McKenna; Shannon E Boye
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

4.  Loss of RPGR glutamylation underlies the pathogenic mechanism of retinal dystrophy caused by TTLL5 mutations.

Authors:  Xun Sun; James H Park; Jessica Gumerson; Zhijian Wu; Anand Swaroop; Haohua Qian; Antonina Roll-Mecak; Tiansen Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

5.  Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis.

Authors:  Cristy A Ku; Vince A Chiodo; Sanford L Boye; Andrew F X Goldberg; Tiansen Li; William W Hauswirth; Visvanathan Ramamurthy
Journal:  Hum Mol Genet       Date:  2011-08-31       Impact factor: 6.150

6.  Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.

Authors:  William A Beltran; Artur V Cideciyan; Shannon E Boye; Guo-Jie Ye; Simone Iwabe; Valerie L Dufour; Luis Felipe Marinho; Malgorzata Swider; Mychajlo S Kosyk; Jin Sha; Sanford L Boye; James J Peterson; C Douglas Witherspoon; John J Alexander; Gui-Shuang Ying; Mark S Shearman; Jeffrey D Chulay; William W Hauswirth; Paul D Gamlin; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2017-05-27       Impact factor: 11.454

7.  Successful gene therapy in the RPGRIP1-deficient dog: a large model of cone-rod dystrophy.

Authors:  Elsa Lhériteau; Lolita Petit; Michel Weber; Guylène Le Meur; Jack-Yves Deschamps; Lyse Libeau; Alexandra Mendes-Madeira; Caroline Guihal; Achille François; Richard Guyon; Nathalie Provost; Françoise Lemoine; Samantha Papal; Aziz El-Amraoui; Marie-Anne Colle; Philippe Moullier; Fabienne Rolling
Journal:  Mol Ther       Date:  2013-10-04       Impact factor: 11.454

Review 8.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

9.  Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 Alters Retinal Structure and Function in Mouse and Macaque.

Authors:  K Tyler McCullough; Sanford L Boye; Diego Fajardo; Kaitlyn Calabro; James J Peterson; Christianne E Strang; Dibyendu Chakraborty; Sebastian Gloskowski; Scott Haskett; Steven Samuelsson; Haiyan Jiang; C Douglas Witherspoon; Paul D Gamlin; Morgan L Maeder; Shannon E Boye
Journal:  Hum Gene Ther       Date:  2018-12-20       Impact factor: 5.695

10.  The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retina.

Authors:  Shannon E Boye; John J Alexander; Sanford L Boye; Clark D Witherspoon; Kristen J Sandefer; Thomas J Conlon; Kirsten Erger; Jingfen Sun; Renee Ryals; Vince A Chiodo; Mark E Clark; Christopher A Girkin; William W Hauswirth; Paul D Gamlin
Journal:  Hum Gene Ther       Date:  2012-09-20       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.